Thursday, July 31, 2014

FDA Approves Beleodaq (belinostat) for Peripheral T-Cell Lymphoma

The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency’s accelerated approval program...


FDA Approves Beleodaq (belinostat) for Peripheral T-Cell Lymphoma

No comments:

Post a Comment